Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

ginkgo bioworks holdings inc - DNA

DNA

Close Chg Chg %
8.35 1.77 21.20%

Closed Market

10.12

+1.77 (21.20%)

Volume: 2.66M

Last Updated:

Feb 6, 2026, 3:59 PM EDT

Trade Now

Company Overview: ginkgo bioworks holdings inc - DNA

DNA Key Data

Open

$8.84

 Day Range

8.65 - 10.23

52 Week Range

5.00 - 17.58

 Market Cap

$476.27M

Shares Outstanding

57.59M

 Public Float

42.57M

Beta

1.56

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$6.23

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

1.05M

  

DNA Performance

1 Week
 
 -7.25%
 
1 Month
 
 -9.96%
 
3 Months
 
 -7.04%
 
1 Year
 
 -41.61%
 
5 Years
 
 N/A
 

DNA Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 3
Full Ratings ➔

About ginkgo bioworks holdings inc - DNA

Ginkgo Bioworks Holdings, Inc. is a biotech company. Its platform enables biotechnology applications across diverse markets, from food, agriculture, industrial chemicals, and pharmaceuticals. It operates through the Cell Engineering and Biosecurity segments. The Cell Engineering segment consists of end-to-end cell engineering solutions and cell engineering tools offerings for biological research and development. The Biosecurity segment focuses on biomonitoring and bioinformatics support services, offered to both government and non-government customers through the company's two core offerings, Canopy and Horizon. The company was founded by Jason Kelly, Reshma Shetty, Bartholomew Canton, Austin Che, and Thomas F. Knight, Jr. in 2008 and is headquartered in Boston, MA.

DNA At a Glance

Ginkgo Bioworks Holdings, Inc.
27 Drydock Avenue
Boston, Massachusetts 02210
Phone 1-877-422-5362 Revenue 227.04M
Industry Medical/Nursing Services Net Income -547,029,000.00
Sector Health Services Employees 834
Fiscal Year-end 12 / 2025
View SEC Filings

DNA Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 2.245
Price to Book Ratio 0.704
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -1.032
Enterprise Value to Sales 1.805
Total Debt to Enterprise Value 1.141

DNA Efficiency

Revenue/Employee 272,233.813
Income Per Employee -655,910.072
Receivables Turnover 10.116
Total Asset Turnover 0.149

DNA Liquidity

Current Ratio 5.619
Quick Ratio 5.619
Cash Ratio 5.29

DNA Profitability

Gross Margin 60.55
Operating Margin -202.737
Pretax Margin -241.147
Net Margin -240.936
Return on Assets -35.956
Return on Equity -60.338
Return on Total Capital -46.21
Return on Invested Capital -44.226

DNA Capital Structure

Total Debt to Total Equity 65.32
Total Debt to Total Capital 39.511
Total Debt to Total Assets 33.956
Long-Term Debt to Equity 61.275
Long-Term Debt to Total Capital 37.065
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Ginkgo Bioworks Holdings Inc - DNA

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
313.84M 477.71M 251.46M 227.04M
Sales Growth
- +52.21% -47.36% -9.71%
Cost of Goods Sold (COGS) incl D&A
144.59M 265.85M 108.81M 89.57M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
29.08M 61.63M 71.55M 63.02M
Depreciation
27.88M 56.03M 55.85M 45.02M
Amortization of Intangibles
1.20M 5.60M 15.70M 18.00M
COGS Growth
- +83.86% -59.07% -17.69%
Gross Income
169.25M 211.86M 142.64M 137.47M
Gross Income Growth
- +25.18% -32.67% -3.62%
Gross Profit Margin
+53.93% +44.35% +56.73% +60.55%
2021 2022 2023 2024 5-year trend
SG&A Expense
2.00B 2.37B 814.87M 597.77M
Research & Development
1.13B 1.05B 525.81M 359.25M
Other SG&A
862.35M 1.32B 289.06M 238.53M
SGA Growth
+39,942,180.00% +18.86% -65.67% -26.64%
Other Operating Expense
- - - -
-
Unusual Expense
(79.34M) (77.94M) 187.01M 114.61M
EBIT after Unusual Expense
(1.75B) (2.08B) (859.24M) (574.91M)
Non Operating Income/Expense
(87.22M) (37.31M) (33.61M) 27.50M
Non-Operating Interest Income
837.00K 20.26M 57.22M 38.61M
Equity in Earnings of Affiliates
- (77.28M) (43.76M) (2.63M)
Interest Expense
2.37M 106.00K 93.00K 94.00K
Interest Expense Growth
- -95.53% -12.26% +1.08%
Gross Interest Expense
2.37M 106.00K 93.00K 94.00K
Interest Capitalized
- - - -
-
Pretax Income
(1.84B) (2.12B) (892.94M) (547.51M)
Pretax Income Growth
-36,762,340.00% -15.41% +57.91% +38.68%
Pretax Margin
-585.69% -444.08% -355.11% -241.15%
Income Tax
(1.48M) (15.03M) (71.00K) (479.00K)
Income Tax - Current - Domestic
1.00K 271.00K 690.00K 566.00K
Income Tax - Current - Foreign
- 159.00K 123.00K (109.00K)
Income Tax - Deferred - Domestic
- - (1.32M) (14.44M)
-
Income Tax - Deferred - Foreign
(156.00K) (1.01M) (884.00K) (936.00K)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- (77.28M) (43.76M) (2.63M)
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(1.84B) (2.11B) (892.87M) (547.03M)
Minority Interest Expense
- - (6.59M) (1.44M)
-
Net Income
(1.83B) (2.10B) (892.87M) (547.03M)
Net Income Growth
-36,600,840.00% -15.02% +57.58% +38.73%
Net Margin Growth
-583.12% -440.63% -355.08% -240.94%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(1.83B) (2.10B) (892.87M) (547.03M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(1.83B) (2.10B) (892.87M) (547.03M)
EPS (Basic)
-45.4276 -50.1452 -18.368 -10.5412
EPS (Basic) Growth
-5,678,350.00% -10.38% +63.37% +42.61%
Basic Shares Outstanding
40.28M 41.98M 48.61M 51.89M
EPS (Diluted)
-46.8828 -50.1452 -18.368 -10.5412
EPS (Diluted) Growth
-5,860,250.00% -6.96% +63.37% +42.61%
Diluted Shares Outstanding
40.28M 41.98M 48.61M 51.89M
EBITDA
(1.80B) (2.10B) (600.68M) (397.28M)
EBITDA Growth
-35,975,720.00% -16.76% +71.40% +33.86%
EBITDA Margin
-573.16% -439.66% -238.88% -174.98%

Snapshot

Average Recommendation HOLD Average Target Price 11.50
Number of Ratings 3 Current Quarters Estimate -1.08
FY Report Date 03 / 2026 Current Year's Estimate -3.98
Last Quarter’s Earnings -1.455 Median PE on CY Estimate N/A
Year Ago Earnings -5.64 Next Fiscal Year Estimate N/A
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 1 1 2 N/A
Mean Estimate -1.08 -1.12 -3.98 N/A
High Estimates -1.08 -1.12 -3.63 N/A
Low Estimate -1.08 -1.12 -4.33 N/A
Coefficient of Variance N/A N/A -12.44 N/A

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 1 1 1
OVERWEIGHT 0 0 0
HOLD 0 0 0
UNDERWEIGHT 1 1 1
SELL 1 1 1
MEAN Hold Hold Hold

Insider Actions for Ginkgo Bioworks Holdings Inc - DNA

Date Name Shares Transaction Value
Jan 23, 2026 Steven P. Coen See remarks N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jan 23, 2026 Steven P. Coen See remarks 4,067 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jan 23, 2026 Steven P. Coen See remarks 9,405 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jan 23, 2026 Steven P. Coen See remarks 8,321 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $8.92 per share 74,223.32
Jan 23, 2026 Steven P. Coen See remarks 9,293 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jan 23, 2026 Steven P. Coen See remarks 8,231 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jan 23, 2026 Steven P. Coen See remarks 8,075 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Sep 11, 2025 Christian O. Henry Director 24,310 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $11.06 per share 268,868.60
Sep 11, 2025 Christian O. Henry Director 34,310 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $10.92 per share 374,665.20
Mar 11, 2025 Mark Dmytruk See remarks 4,245 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 7, 2025 Mark Dmytruk See remarks 20,632 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 7, 2025 Mark Dmytruk See remarks 10,876 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 7, 2025 Mark Dmytruk See remarks 4,522 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 7, 2025 Mark Dmytruk See remarks 34,652 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $7.72 per share 267,513.44
Mar 7, 2025 Mark Dmytruk See remarks 35,442 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 7, 2025 Mark Dmytruk See remarks 34,870 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 7, 2025 Mark Dmytruk See remarks 21,204 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00

Ginkgo Bioworks Holdings Inc in the News